Investment supports application of ViaNautis’ polyNaut

投资支持ViaNautis的polyNaut应用

®

®

platform to regenerative therapies for spinal cord injury, where targeted delivery remains a huge barrier

脊髓损伤再生疗法的平台，其中靶向递送仍然是一个巨大的障碍

Adds a new high-value CNS indication and provides further validation of polyNaut

新增一项高价值的中枢神经系统适应症，并进一步验证 polyNaut

®

®

as a versatile platform for precise, non-viral delivery of genetic medicines

作为用于精准、非病毒递送基因药物的多功能平台

CAMBRIDGE, United Kingdom, Sept. 09, 2026 (GLOBE NEWSWIRE) -- ViaNautis Bio ('ViaNautis'), the biotech developing polyNaut

英国剑桥，2026年9月9日（环球新闻网）——开发polyNaut的生物科技公司ViaNautis Bio（“ViaNautis”）

®

®

for precise, non‑viral delivery of genetic medicines, today announced that

为实现基因药物的精准、非病毒递送，今日宣布

SCI Ventures

SCI 创投

, a specialist venture fund backed by leading clinical centres and research foundations worldwide focused on advancing treatments and cures for paralysis, has joined the company as a new investor. The investment expands ViaNautis' central nervous system (CNS) portfolio to include chronic spinal cord injury (SCI), an area of high unmet medical need where no regenerative therapies have yet been approved..

，一家由全球领先临床中心和研究基金会支持、专注于推进瘫痪治疗与治愈方案的专业风险投资基金，已作为新投资者加入该公司。此次投资扩大了ViaNautis在中枢神经系统（CNS）领域的产品组合，将其拓展至慢性脊髓损伤（SCI）领域；该领域存在巨大的未满足医疗需求，且目前尚无获批的再生疗法。

Globally, more than 20 million people are living with spinal cord injury, a condition associated with lifelong morbidity and lifetime costs that can exceed several million dollars per patient. Current treatment options are largely limited to rehabilitation and symptomatic management. While regenerative approaches are generating increasing momentum, delivering therapeutic payloads to the right cells at the site of injury remains one of the field's greatest challenges..

在全球范围内，有超过2000万人患有脊髓损伤，这是一种与终身残疾相关的疾病，每位患者的终生治疗费用可能高达数百万美元。目前的治疗选择主要局限于康复治疗和症状管理。尽管再生疗法正日益受到关注，但如何将治疗药物精准递送至损伤部位的靶细胞，仍然是该领域面临的最大挑战之一。

'Spinal cord injury is one of the clearest examples of a disease area where delivery remains a key limiting factor,'

“脊髓损伤是疾病领域中最清晰的例子之一，其中递送仍然是一个关键的 limiting factor。”

said Adi Hoess, Chief Executive Officer of ViaNautis

ViaNautis 首席执行官阿迪·赫斯表示

. 'polyNaut

. 'polyNaut

®

®

was designed to precisely overcome these challenges by enabling targeted, non-viral systemic delivery of regenerative payloads to defined cell populations at or around the lesion site, while avoiding payload limitations and immunogenicity challenges associated with viral vectors. With the support of SCI Ventures, we are expanding our CNS portfolio into spinal cord injury and exploring how precise delivery can unlock new regenerative approaches for patients who continue to have very limited treatment options.'.

该设计旨在通过向损伤部位或其周围的特定细胞群体精准、非病毒性地全身递送再生性载荷，从而精确克服这些挑战，同时避免与病毒载体相关的载荷局限性及免疫原性问题。在SCI Ventures的支持下，我们正在将中枢神经系统产品组合拓展至脊髓损伤领域，并探索精准递送如何为治疗选择仍然极为有限的患者开启新的再生疗法途径。

ViaNautis aims to address this challenge with polyNaut

ViaNautis 旨在通过 polyNaut 应对这一挑战

®

®

, its targeted polymer nanovesicles (tPNVs), which enable plug-and-play, nanobody-guided delivery of nucleic acid payloads to specific cells and tissues, including regenerative genetic payloads to cells at and around spinal cord lesions.

，其靶向聚合物纳米囊泡（tPNVs）能够实现即插即用、由纳米抗体引导的核酸载荷向特定细胞和组织的递送，包括向脊髓损伤部位及周围细胞递送再生性基因载荷。

'We are seeing many promising scientific advances in the laboratory but translating these discoveries into meaningful therapies remains a major challenge,'

“我们在实验室中看到了许多有前景的科学进展，但将这些发现转化为具有实际意义的疗法仍然是一个重大挑战。”

commented Adrien Cohen, Founding Managing Director of SCI Ventures

SCI Ventures 的创始管理董事 Adrien Cohen 评论道

. 'What drew us to ViaNautis was the potential of its polyNaut

. “吸引我们关注ViaNautis的是其polyNaut的潜力

®

®

platform and precise targeting capabilities to overcome one of the most significant hurdles in spinal cord injury: delivery. We are excited to support the company's expansion into this important indication.'

平台及精准靶向能力，以克服脊髓损伤领域最重大的挑战之一：药物递送。我们很高兴支持该公司拓展这一重要适应症。

The SCI programme builds on ViaNautis' broader CNS strategy and further demonstrates the versatility of the polyNaut

SCI计划建立在ViaNautis更广泛的CNS战略基础上，并进一步展示了polyNaut的多功能性。

®

注册商标符号

platform across diseases where targeted delivery remains the key barrier to unlocking the potential of genetic medicines.

跨疾病平台，其中靶向递送仍然是释放基因药物潜力的关键障碍。

For more information, please contact:

如需更多信息，请联系：

Optimum Strategic Communications

奥普蒂姆战略传播

Zoe Bolt, Eleanor Cooper, Henry Williams

佐伊·博尔特，埃莉诺·库珀，亨利·威廉姆斯

Tel: +44 (0) 20 388 296 21

电话：+44 (0) 20 388 296 21

Email:

电子邮件：

ViaNautis@optimumcomms.com

ViaNautis@optimumcomms.com

About ViaNautis Bio

关于 ViaNautis Bio

ViaNautis is revolutionising genetic medicine delivery with polyNaut

ViaNautis 正通过 polyNaut 革新基因药物的递送方式

®

®

, its targeted polymer nanovesicles (tPNVs) across multiple indications. polyNaut

，其针对多种适应症的靶向聚合物纳米囊泡（tPNVs）。polyNaut

®

®

provides a versatile, plug-and-play solution for nanobody-based receptor-mediated delivery of DNA and mRNA to any cell type. By leveraging the broad applicability of tPNVs, ViaNautis is advancing a pipeline across CNS, immunology, oncology and respiratory diseases.

为基于纳米抗体的受体介导DNA和mRNA递送至任何细胞类型提供了一种多功能、即插即用的解决方案。通过利用tPNVs的广泛适用性，ViaNautis正在推进涵盖中枢神经系统、免疫学、肿瘤学和呼吸系统疾病的产品管线。

With polyNaut

使用 polyNaut

®

®

, ViaNautis has built a differentiated non-viral delivery platform – targeted, safe, convenient, redosable and scalable – that promises to widen the reach of genetic medicines to more people in need.

ViaNautis 已构建出一个差异化的非病毒递送平台——具备靶向性、安全性、便捷性、可重复给药及可扩展性——有望扩大基因药物的覆盖范围，惠及更多有需要的患者。

The Company is backed by blue-chip investors, including 4BIO Capital, BGF and UCB Ventures, and has strategic partnerships with Eli Lilly and the Cystic Fibrosis Foundation. For further information, please visit:

该公司获得包括4BIO Capital、BGF和UCB Ventures在内的蓝筹投资者支持，并与礼来公司及囊性纤维化基金会建立了战略合作伙伴关系。如需更多信息，请访问：

https://vianautis.com/

https://vianautis.com/

About SCI Ventures

关于 SCI Ventures

SCI Ventures is the world’s first mission-driven fund focused on neuro-restoration and paralysis. Backed by leading global foundations and advised by world-class neuroscientists, SCI Ventures aims to catalyze the development of the next generation of treatments with an emphasis on technology to restore function and cure-oriented therapies.

SCI Ventures 是全球首个以使命为驱动、专注于神经修复与瘫痪治疗的基金。该基金由全球领先的基础性机构支持，并由世界一流的神经科学家提供顾问指导，旨在加速下一代治疗方法的开发，重点聚焦于通过技术恢复功能以及以治愈为导向的疗法。

SCI Ventures pairs capital with strategic support, clinical validation, and access to a global network of partners to de-risk innovation and accelerate patient impact. More information about SCI Ventures and its portfolio can be found at .

SCI Ventures 将资本与战略支持、临床验证以及全球合作伙伴网络相结合，以降低创新风险并加速对患者产生积极影响。有关 SCI Ventures 及其投资组合的更多信息，请访问 。

https://www.sciventures.com/

https://www.sciventures.com/